Four Unproven IV Therapies for ME/CFS: What the Evidence Actually Shows

Yoon Hang Kim MD

— 15 min read
Share
Four Unproven IV Therapies for ME/CFS: What the Evidence Actually Shows
Photo by Adrian Swancar / Unsplash

Nov 11, 2026 · @Yoon Hang Kim MD

Yoon Hang Kim MD is a board-certified preventive medicine physician who practices integrative and functional medicine. He is a University of Arizona Osher Fellow (trained under Dr. Andrew Weil), holds the UCLA medical acupuncture certification, and is a recipient of the IFM Scholarship. He is the author of eight books — including LDN Primer, LDN for Clinicians, MCAS: Epidemic in Plain Sight, and Integrative Oncology: Evidence-Based Strategies to Support Cancer Treatment — and more than 25 peer-reviewed articles. He founded the LDN Support Group (~10,000 members) and previously served as Enterprise Medical Director at WellMed/Optum, Medical Director of Integrative Oncology at Miami Cancer Institute, and Director of the Integrative Medicine Program at the University of Kansas Medical Center.

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remains without an FDA-approved treatment, leaving patients vulnerable to unproven interventions marketed as cutting-edge solutions. This review evaluates the clinical evidence for four intravenous therapies increasingly offered to ME/CFS patients: extracorporeal blood oxygenation and ozonation (EBOO), IV methylene blue, IV procaine, and IV mesenchymal stromal cell (MSC) infusions. None has convincing controlled trial evidence of efficacy in ME/CFS. EBOO draws on a 200-patient uncontrolled study of a different procedure (autohemotherapy); IV methylene blue has laboratory-level mitochondrial rationale but no ME/CFS patient trials and carries serious drug-interaction risks; IV procaine has the weakest disease-specific evidence base of the four; and commercial MSC infusions, while scientifically credible as a research platform, lack standardization and ME/CFS-specific efficacy data. These therapies are contrasted with interventions that have stronger — though still incomplete — evidence, including energy management and pacing (guideline-supported), CoQ10 plus NADH supplementation (one positive RCT, needs replication), low-dose naltrexone (promising observational data, controlled trials pending), and acupuncture (positive but low-certainty signals). The same evidentiary standard is applied throughout. Biological plausibility is distinguished from clinical proof, and a six-point framework for evaluating ME/CFS treatment claims is proposed.

The Gap Between a Good Hypothesis and Good Evidence

Patients with ME/CFS are desperate for relief — and understandably so. With no FDA-approved treatment and an illness that strips people of their ability to work, think clearly, and participate in daily life, the appeal of novel IV therapies is real. Clinics now market extracorporeal blood oxygenation and ozonation (EBOO), intravenous methylene blue, IV procaine, and IV mesenchymal stromal cell (MSC) infusions as cutting-edge options for ME/CFS.

Each of these therapies carries at least a kernel of biological plausibility. But plausibility is not proof. The distance between "this mechanism could theoretically help" and "this treatment reliably improves post-exertional malaise and sustained daily function" is vast — and it is precisely where patients deserve intellectual honesty from their clinicians.

This post walks through the evidence (and the absence of evidence) for each of these four therapies. None has convincing controlled trial data in ME/CFS. There are meaningful differences between them, however, and those differences matter for informed consent.

ME/CFS: Where the Treatment Landscape Actually Stands

Myalgic encephalomyelitis/chronic fatigue syndrome is a chronic, multi-system neuroimmunological disorder. Its hallmark is post-exertional malaise (PEM) — a disproportionate worsening of symptoms following physical, cognitive, or emotional exertion that can last days to weeks. Additional features include unrefreshing sleep, cognitive impairment ("brain fog"), orthostatic intolerance, widespread pain, and immune dysfunction.

The pathophysiology remains incompletely understood, but converging lines of evidence implicate immune dysregulation, mitochondrial bioenergetic impairment, oxidative and nitrosative stress, neuroinflammation, and autonomic nervous system dysfunction. Post-COVID syndrome has brought renewed attention to ME/CFS, as a significant proportion of long COVID patients meet diagnostic criteria for ME/CFS.

The 2021 NICE guideline was a watershed moment. It formally removed graded exercise therapy (GET) as a recommended treatment — acknowledging that forced, quota-based exercise increments can worsen the condition. It also repositioned cognitive behavioral therapy (CBT) from a standalone treatment to a supportive intervention for coping with chronic illness, not a cure. The guideline endorsed energy management and activity pacing as the cornerstone of self-management.

Currently, evidence-supported approaches include individualized energy management and pacing, sleep optimization, treatment of orthostatic intolerance, pain management, and — where the evidence is building — interventions targeting mitochondrial function (CoQ10 plus NADH showed significant fatigue reduction in a 207-patient randomized controlled trial) and low-dose naltrexone (LDN), which demonstrated symptomatic improvement in roughly 74% of 218 ME/CFS patients in a retrospective analysis, with a good safety profile and biological plausibility through TRPM3 ion channel restoration in natural killer cells.

It is against this backdrop — a disease without a cure, a patient population that has been historically dismissed, and a legitimate biological rationale for exploring novel therapies — that we must evaluate each of the four IV treatments below with clear eyes and honest language.

EBOO: Extracorporeal Blood Oxygenation and Ozonation

EBOO involves withdrawing a patient's blood, passing it through an extracorporeal circuit where it is exposed to an ozone-oxygen mixture, and returning it to the body. It is marketed as a way to "detoxify" the blood and improve oxygenation at the cellular level.

What the evidence actually shows. There is no published, controlled clinical trial of EBOO specifically in ME/CFS patients. The study most frequently cited in marketing materials is a 200-patient uncontrolled study published in 2021 — but it tested a different procedure: oxygen-ozone autohemotherapy, which treats a withdrawn portion of blood rather than circulating it through a full extracorporeal system. That study reported that 77.5% of patients showed improvement on the Fatigue Severity Scale at roughly 30 days, with no reported adverse effects through three months.

That signal is worth investigating further. But it is not a reliable estimate of treatment effectiveness. There was no randomized control group and no sham-treatment comparator. Outcomes were self-reported fatigue, not sustained functional capacity or reduction in post-exertional malaise. Without a comparator arm, the study cannot distinguish a genuine treatment effect from natural symptom fluctuation, regression to the mean, or expectation effects.

More critically, autohemotherapy and EBOO are not the same procedure. They differ in blood volume handled, ozone exposure dynamics, anticoagulation requirements, and extracorporeal circulation burden. Published EBOO research has largely focused on other conditions, including peripheral arterial disease. Treating these procedures as interchangeable is not scientifically justified.

The risks. EBOO involves vascular access, blood handling, and anticoagulation. The risk profile includes access site complications, bleeding, circuit-related problems, and potential oxidative injury. Small case series reporting no adverse events cannot reliably exclude uncommon but serious harms.

Clinical assessment. The advertised "70–80% response rate" should not be presented as an established EBOO response rate for ME/CFS. The evidence is insufficient to justify routine clinical use.

IV Methylene Blue: Interesting Chemistry, Missing Clinical Evidence

Methylene blue is a fascinating molecule. It participates in oxidation-reduction reactions, can serve as an alternative electron carrier within mitochondria, and has demonstrated effects on mitochondrial respiration, oxidative stress, and neuroinflammation in cell and animal models. Its FDA-approved indication is acquired methemoglobinemia — a specific, well-defined use case.

The logical chain being marketed to ME/CFS patients goes something like this: mitochondrial dysfunction is implicated in ME/CFS; methylene blue affects mitochondrial electron transport; therefore, IV methylene blue should help ME/CFS. This is a category error. "Affects mitochondria" and "treats a disease involving mitochondrial dysfunction" are not the same claim. The second requires controlled human trials demonstrating that the intervention improves post-exertional malaise, sustained function, or disease course in properly diagnosed ME/CFS patients. Those trials do not exist.

There is no established ME/CFS dose, treatment schedule, or evidence that IV administration offers any advantage over oral dosing for this indication.

The risks are better established than the benefits. The FDA label for methylene blue carries a boxed warning for potentially fatal serotonin syndrome when combined with serotonergic medications — a category that includes most commonly prescribed antidepressants (SSRIs, SNRIs), tramadol, and dextromethorphan. Many ME/CFS patients take one or more of these medications. Methylene blue is also contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of severe hemolysis. Higher doses can cause cardiovascular and neurologic toxicity, and paradoxically, methemoglobinemia.

Asking a patient to discontinue a helpful antidepressant in order to receive an unproven infusion introduces a tangible harm in pursuit of an undemonstrated benefit. That calculus matters.

Clinical assessment. This is a research hypothesis, not an evidence-based ME/CFS infusion. Interesting enough for a carefully designed clinical trial, but not for routine clinical use.

IV Procaine: The Weakest Case of the Four

Procaine is a local anesthetic. It has well-established properties for regional and local anesthesia. Its pharmacologic effects — sodium channel blockade, membrane stabilization — are well characterized. None of that translates automatically to a systemic treatment for ME/CFS.

There is no published controlled clinical trial establishing that IV procaine improves ME/CFS symptoms, reduces post-exertional malaise, or modifies the disease in any measurable way. The related literature on "neural therapy" — local injection of procaine for pain conditions including fibromyalgia — involves a different patient population, different administration techniques, and different outcome measures. It cannot be extrapolated to conclude that systemic IV procaine treats ME/CFS.

Local analgesia or transient relaxation from a procaine infusion should not be confused with treatment of the underlying disease.

The risks. The procaine prescribing information describes local-anesthetic systemic toxicity (LAST) when plasma concentrations become excessive. This includes dizziness, tinnitus, tremor, and seizures; respiratory depression or arrest; and hypotension, myocardial depression, heart block, ventricular arrhythmias, and cardiac arrest. These warnings do not mean every slow, low-dose infusion is dangerous — but they do mean that safety depends critically on dosing, delivery rate, patient factors, and the clinical setting's ability to recognize and treat LAST.

Clinical assessment. Of these four options, IV procaine has the weakest disease-specific evidence base. There is no demonstrated ME/CFS benefit to weigh against the pharmacologic risks.

IV Mesenchymal Stromal Cells: Legitimate Science, Premature Application

Mesenchymal stromal cells (MSCs) have genuine immunomodulatory and anti-inflammatory activity. They represent a scientifically credible research platform, and in December 2024, the FDA approved the first MSC product — Ryoncil, a donor bone-marrow-derived preparation — for steroid-refractory acute graft-versus-host disease in pediatric patients.

That approval does not extend to ME/CFS, and it does not validate unrelated commercial cell preparations. "MSCs" describe a category of cells, not a standardized, interchangeable drug product. Products differ enormously by cell source (bone marrow, adipose tissue, umbilical cord), processing method, viability, potency, and dose. Safety data from one regulated product cannot be assumed to apply to a differently manufactured commercial offering.

There is no convincing published clinical trial demonstrating that MSC infusion produces durable improvement in post-exertional malaise, fatigue, or functional capacity in ME/CFS patients. Trials in other diseases provide safety and feasibility data but cannot establish efficacy in a different condition.

The risks. These include acute infusion reactions, hypersensitivity reactions, potential transmission of infectious agents, product-to-product variability, and uncertain longer-term effects. FDA labeling for the approved MSC product carries a warning about ectopic tissue formation.

Clinical assessment. This is potentially legitimate research, but it is not a treatment I would recommend purchasing outside of a properly regulated clinical trial. The distinction matters: participating in a trial under an institutional review board, with informed consent, standardized product, and systematic adverse event collection is fundamentally different from buying an IV infusion from a commercial clinic.

What Would Make a Claim Convincing?

Before accepting any novel IV therapy as an ME/CFS treatment, I would want the provider to produce evidence — not testimonials, not changes in inflammatory markers — that answers six questions:

  1. Were participants diagnosed with ME/CFS including post-exertional malaise? Many studies use the older Fukuda criteria, which capture chronic fatigue broadly but may not require PEM. A study of "chronically fatigued" people is not a study of ME/CFS.
  2. Was the exact procedure or product tested? Not a related ozone technique, a different route of administration, or a different cell preparation. EBOO is not autohemotherapy. One MSC product is not another.
  3. Was there randomization and an appropriate control? A sham-controlled or placebo-controlled design is essential. Open-label studies cannot account for the powerful effects of expectation, clinical attention, and natural symptom fluctuation.
  4. Did outcomes include delayed post-exertional worsening and sustained daily function? Feeling energized for an hour after an infusion is not the same as being able to sustain normal activities over weeks without crashing. Self-reported fatigue scales alone are insufficient.
  5. Were adverse events, deterioration, and dropouts collected systematically? Studies that only report positive outcomes are not informative about safety. ME/CFS patients are vulnerable to post-exertional deterioration, and any intervention must account for this.
  6. Did benefit persist after treatment stopped? Transient symptomatic relief during a course of infusions may reflect the treatment environment rather than a durable biological effect.

"No convincing evidence" does not prove that a treatment cannot work. It means that we cannot reliably estimate its benefit, identify who might respond, or establish that the potential benefits outweigh the known risks. For informed consent, all four of these therapies should be described as unproven for ME/CFS — not as established treatments with merely "variable response rates."

What Current Evidence Supports — and Where Evidence Is Emerging

The absence of a cure does not mean the absence of useful interventions. But intellectual honesty requires that we grade these interventions by the same standard we applied to the four IV therapies above. Some approaches rest on guideline-level consensus; others show promise but remain incompletely established. The distinction matters.

Energy management and activity pacing. This is the cornerstone of ME/CFS self-management, endorsed by the 2021 NICE guideline and supported by a 2024 meta-analysis showing the highest patient adherence among management strategies. The principle is straightforward: stay within your energy envelope, break tasks into manageable segments, and avoid the boom-bust cycle that triggers PEM.

Sleep optimization. Unrefreshing sleep is a core ME/CFS symptom. Addressing sleep hygiene, treating comorbid sleep disorders, and — in selected patients — judicious use of low-dose sleep aids can make a real difference in daily function.

Orthostatic symptom management. Many ME/CFS patients have concurrent POTS or orthostatic intolerance. Volume expansion, compression garments, counter-maneuvers, and in some cases pharmacologic support (fludrocortisone, midodrine, ivabradine) can improve upright tolerance.

Mitochondrial support — promising RCT evidence, needs replication. A 12-week, randomized, double-blind, placebo-controlled trial in 207 ME/CFS patients found that CoQ10 (200 mg/day) plus NADH (20 mg/day) significantly reduced cognitive fatigue and improved health-related quality of life. A 2025 narrative review of micronutritional strategies for mitochondrial dysfunction in ME/CFS further supports the rationale for NAD+ precursors, B-complex vitamins, magnesium, and CoQ10 — acknowledging that mitochondrial dysfunction is likely one contributor among several, not the sole cause.

Low-dose naltrexone (LDN) — promising but incompletely established. LDN is clinically promising but remains inadequately tested in ME/CFS by controlled trial standards. A retrospective analysis of 218 ME/CFS patients treated with LDN (3.0–4.5 mg/day) found that 73.9% reported some symptomatic improvement, most commonly in vigilance, physical performance, or cognitive function. Only 7% discontinued due to side effects, and no severe adverse effects were reported. However, without randomization or a placebo group, that percentage cannot be interpreted as an established response rate — the same limitation we noted for the EBOO autohemotherapy data. The study's own authors call for prospective controlled trials to confirm feasibility. Mechanistic studies provide a rationale for LDN, including experimental evidence that naltrexone can normalize impaired TRPM3-mediated calcium signaling in NK cells from patients with ME/CFS. Whether this mechanism explains clinical benefit remains uncertain. A randomized controlled trial of LDN in post-COVID fatigue syndrome (which closely overlaps with ME/CFS) is currently registered and underway — and its results will substantially clarify the picture.

Acupuncture — positive signals, low-certainty evidence. Several systematic reviews, including a 2025 network meta-analysis comparing different acupuncture methods for CFS, report improvements in fatigue measures. However, confidence in these findings is limited by small studies, high heterogeneity, risk of bias, inconsistent diagnostic criteria (many studies use Fukuda rather than criteria requiring PEM), and — critically — limited or absent assessment of post-exertional malaise as an outcome. Studies are heavily concentrated in Chinese-language databases, raising questions about generalizability. Acupuncture may be reasonable as an individualized symptomatic adjunct when patients find it helpful, but current evidence does not establish it as a disease-modifying treatment for ME/CFS.

CBT as supportive care — not a treatment for the disease. CBT should not be presented as treatment for the underlying disease. The 2021 NICE guideline recommends it only as an optional supportive intervention for symptom management, functioning, and distress — not as a cure. A November 2025 meta-analysis reported benefits in selected CBT subgroups (individual face-to-face CBT for fatigue; self-directed CBT for physical functioning), but overall effects were inconsistent, heterogeneity was very high (generally exceeding 90%), and sustained follow-up benefit was not demonstrated. Subsequent commentary has questioned whether included populations consistently met PEM-defined ME/CFS diagnostic criteria. CBT's role is therefore supportive and preference-sensitive rather than disease-modifying — and when it is positioned honestly in that frame, it can help people cope with the grief, loss of identity, and uncertainty that accompany chronic illness. Presented as a cure, it causes harm.

The Bottom Line

ME/CFS patients deserve more than "we don't have anything for you" — but they also deserve more than being sold unproven infusions at premium prices. Both extremes cause harm.

The honest clinical picture looks like this: we have interventions that meaningfully help with symptom management (pacing, sleep optimization, orthostatic support), a growing evidence base for mitochondrial-targeted nutraceuticals (CoQ10 + NADH) and low-dose naltrexone, acupuncture signals that justify individualized use, and CBT that — when positioned honestly as supportive care — can help people cope with a devastating illness.

Applying one consistent evidence standard across all of these interventions — including the ones I use — the hierarchy looks like this: pacing and energy management are guideline-supported; orthostatic and sleep management are clinically established care for ME/CFS manifestations; CoQ10 plus NADH has promising RCT evidence that needs replication; LDN has promising observational and mechanistic evidence, but controlled efficacy is not yet established; acupuncture has positive but low-certainty, heterogeneous trial evidence; EBOO has insufficient disease-specific controlled evidence; IV methylene blue is mechanistically interesting with essentially no ME/CFS efficacy data; IV procaine has very weak disease-specific evidence; and commercial MSC infusions represent a legitimate research platform but lack evidence for clinical ME/CFS treatment outside of regulated trials. That hierarchy is the point — the same evidentiary standard must apply whether I personally use the therapy or not.

If a patient chooses to pursue one of these therapies, the informed consent conversation should be transparent: this is unproven for your condition, the response rates advertised are not established by controlled research, there are specific risks we need to discuss, and there are evidence-supported alternatives that should be maximized first.

The standard I hold myself to — and that I believe every clinician should hold themselves to — is this: do the interventions with the best evidence first, do them well, and reserve experimental therapies for properly regulated clinical trials or genuinely last-resort situations where the evidence hierarchy has been exhausted and the patient fully understands what they are and are not buying.

That is not nihilism. That is intellectual honesty in service of the people we are supposed to be helping.

Conclusion

The ME/CFS treatment landscape is simultaneously underfunded and oversold. Patients face a paradox: the medical establishment has historically offered too little, while the wellness marketplace now offers too much — often at premium prices and without the evidentiary transparency patients deserve.

This review applied a single, consistent evidence standard to nine interventions spanning the spectrum from guideline-supported management to speculative infusions. The results are sobering but not nihilistic. Energy management and pacing have the strongest institutional support. Orthostatic and sleep management represent established care for specific ME/CFS manifestations. CoQ10 plus NADH supplementation has crossed the threshold of a positive randomized controlled trial — a meaningful step, though replication is needed. Low-dose naltrexone has accumulated encouraging observational data and a plausible mechanism, but the controlled trial that would convert promise into proof is still underway. Acupuncture produces consistent fatigue-reduction signals across systematic reviews, but low certainty, high heterogeneity, and absent PEM outcome assessment keep it in the adjunctive column.

On the other side of the ledger, EBOO, IV methylene blue, IV procaine, and commercial MSC infusions all fail to meet a reasonable evidence threshold for routine ME/CFS treatment. Each has some degree of biological rationale — ranging from genuine scientific interest (MSCs, methylene blue) to largely speculative (IV procaine) — but rationale without controlled patient evidence is not a treatment recommendation.

The six-point evidence framework proposed in this article is not intended as an academic exercise. It is a practical tool for clinicians and patients navigating a commercial landscape that routinely conflates hypothesis with proof. Any provider offering these therapies has a duty to present them as unproven — not as established treatments with variable response rates.

For clinicians treating ME/CFS, the path forward requires holding two truths simultaneously: our patients need more therapeutic options, and they need those options to be vetted honestly. The standard I hold myself to — and that I believe every clinician should hold themselves to — is this: maximize the interventions with the best evidence first, do them well, and reserve experimental therapies for properly regulated clinical trials or genuinely last-resort situations where the patient fully understands what they are and are not purchasing.

That is not therapeutic nihilism. That is the intellectual honesty our patients have always deserved.

Sources

Work with Dr. Kim

Dr. Kim runs a membership-based, insurance-free telemedicine practice serving patients in Iowa, Illinois, Missouri, Georgia, Florida, and Texas. His practice is capped at 99 active clients to ensure personalized, unhurried care — with a focus on complex conditions including ME/CFS, mast cell activation syndrome (MCAS), chronic pain, and integrative oncology support.

His approach combines evidence-based conventional medicine with integrative and functional medicine tools — including medical acupuncture, low-dose naltrexone, mitochondrial support, and individualized treatment plans built around what the evidence actually shows.

If you are looking for a physician who will be transparent about what is proven, what is promising, and what remains speculative — and who will partner with you in navigating a complex illness — Dr. Kim may be a good fit.

Website: www.yoonhangkim.com

To schedule a consultation or learn about membership: www.directintegrativecare.com

Read more